2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005050487v1 16/10/3128    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teutonico, A. Articles by Di Paolo, S. Search for Related Content PubMed PubMed Citation Articles by Teutonico, A. Articles by Di Paolo, S.

Glucose Metabolism in Renal Transplant Recipients: Effect of Calcineurin Inhibitor Withdrawal and Conversion to Sirolimus

Department of Emergency and Organ Transplants, Division of Nephrology, Dialysis and Transplantation, University of Bari, Policlinico, Bari, Italy

Address correspondence to: Dr. Salvatore Di Paolo, Department of Emergency and Organ Transplants, Division of Nephrology, Dialysis and Transplantation, University of Bari, Policlinico-Piazza Giulio Cesare 11, Bari 70124, Italy. Phone: 39-080-5593231; Fax: 39-080-5593227; E-mail: s.dipaolo{at}nephro.uniba.it

Received for publication May 11, 2005. Accepted for publication July 16, 2005.

Cyclosporine A (CsA) and tacrolimus have been associated with an increased risk for diabetes after transplantation, whereas sirolimus is deemed to be devoid of any effect on glucose metabolism. This study was performed to investigate the effect of the withdrawal of calcineurin inhibitors and the switch to sirolimus on peripheral insulin resistance and pancreatic cell response. Twenty-six patients who received a kidney transplant and discontinued CsA and were converted to sirolimus and 15 recipients of suboptimal kidneys who were treated with tacrolimus plus sirolimus for the first 3 mo after grafting and thereafter with sirolimus alone were enrolled. All patients underwent an oral glucose tolerance test and intravenous insulin tolerance test before and 6 mo after the conversion to sirolimus-alone therapy. The withdrawal of CsA or tacrolimus was associated with a significant fall of insulin sensitivity (both P = 0.01) and with a defect in the compensatory cell response, as measured by the disposition index (P = 0.004 and P = 0.02, respectively). The increase of insulin resistance and the decrease of disposition index significantly correlated with the change of serum triglyceride concentration after the conversion to sirolimus-based therapy (R² = 0.30, P = 0.0002; and R² = 0.19, P = 0.004, respectively). Clinically, the switch to sirolimus was associated with a 30% increase of incidence of impaired glucose tolerance and with four patients’ developing new-onset diabetes. In conclusion, the discontinuation of calcineurin inhibitors and their replacement by sirolimus fail to ameliorate the glycometabolic profile of kidney transplant recipients. Rather, it is associated with a worsening of insulin resistance and an inappropriately low insulin response.

This article has been cited by other articles:

				O. Johnston, C. L. Rose, A. C. Webster, and J. S. Gill Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1411 - 1418. [Full Text] [PDF]

				M. Pavlakis and A. S. Goldfarb-Rumyantzev Diabetes after Transplantation and Sirolimus: What's the Connection? J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1255 - 1256. [Full Text] [PDF]

				S. Chadban New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1816 - 1818. [Full Text] [PDF]

				A. C. Shirali and M. J. Bia Management of Cardiovascular Disease in Renal Transplant Recipients Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504. [Abstract] [Full Text] [PDF]

				R. D. Bloom and M. F. Crutchlow New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S38 - S48. [Abstract] [Full Text] [PDF]

				J. Hjelmesaeth, L. T. Hagen, A. Asberg, K. Midtvedt, O. Storset, C. E. Halvorsen, L. Morkrid, A. Hartmann, and T. Jenssen The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1743 - 1749. [Abstract] [Full Text] [PDF]

				M. Krebs, B. Brunmair, A. Brehm, M. Artwohl, J. Szendroedi, P. Nowotny, E. Roth, C. Furnsinn, M. Promintzer, C. Anderwald, et al. The Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man Diabetes, June 1, 2007; 56(6): 1600 - 1607. [Abstract] [Full Text] [PDF]

				K. Y. Hur, M. S. Kim, Y. S. Kim, E. S. Kang, J. H. Nam, S. H. Kim, C. M. Nam, C. W. Ahn, B. S. Cha, S. I. Kim, et al. Risk Factors Associated With the Onset and Progression of Posttransplantation Diabetes in Renal Allograft Recipients Diabetes Care, March 1, 2007; 30(3): 609 - 615. [Abstract] [Full Text] [PDF]

				M. F. Crutchlow and R. D. Bloom Transplant-Associated Hyperglycemia: A New Look at an Old Problem Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 343 - 355. [Abstract] [Full Text] [PDF]

				E. Rodrigo, G. Fernandez-Fresnedo, R. Valero, J. C. Ruiz, C. Pinera, R. Palomar, J. Gonzalez-Cotorruelo, C. Gomez-Alamillo, and M. Arias New-Onset Diabetes after Kidney Transplantation: Risk Factors J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S291 - S295. [Abstract] [Full Text] [PDF]

				N. Zhang, D. Su, S. Qu, T. Tse, R. Bottino, A.N. Balamurugan, J. Xu, J. S. Bromberg, and H. H. Dong Sirolimus Is Associated With Reduced Islet Engraftment and Impaired {beta}-Cell Function Diabetes, September 1, 2006; 55(9): 2429 - 2436. [Abstract] [Full Text] [PDF]

				S. Di Paolo, A. Teutonico, D. Leogrande, C. Capobianco, and P. F. Schena Chronic Inhibition of Mammalian Target of Rapamycin Signaling Downregulates Insulin Receptor Substrates 1 and 2 and AKT Activation: A Crossroad between Cancer and Diabetes? J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2236 - 2244. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673